Department of Internal Medicine, Texas Tech University Health Sciences Center at El Paso, El Paso, Texas.
Division of Cardiovascular Medicine, North Shore-Long Island Jewish Medical Centers, Northwell Health.
Curr Opin Cardiol. 2022 Jul 1;37(4):350-355. doi: 10.1097/HCO.0000000000000955. Epub 2022 Feb 16.
Cardiovascular disease is the most common cause of morbidity and mortality worldwide, and the risk is heightened in the presence of obesity. We review semaglutide, a drug recently approved for chronic weight management in adults with obesity or who are overweight.
On 4 June 2021, the US Food and Drug Administration approved semaglutide injection at 2.4 mg once weekly for chronic weight management in adults with obesity or overweight with at least one weight-related condition such as high blood pressure, type 2 diabetes mellitus, or high cholesterol. This subcutaneous injection is the first approved drug for chronic weight management in adults with general obesity or overweight since 2014. The drug is indicated for weight management in patients with a BMI of 27 kg/m2 or greater who have at least one weight-related ailment or in patients with a BMI of 30 kg/m2 or greater.
Semaglutide offers adults with obesity or overweight a new treatment in conjunction with a weight management program consisting of reduced calorie diet and increased physical activity.
心血管疾病是全世界发病率和死亡率最高的疾病，而肥胖会增加患病风险。我们将对司美格鲁肽进行综述，这是一种最近被批准用于肥胖或超重成人慢性体重管理的药物。
2021 年 6 月 4 日，美国食品和药物管理局批准每周皮下注射 2.4mg 司美格鲁肽用于肥胖或超重成人的慢性体重管理，这些患者至少有一种与体重相关的疾病，如高血压、2 型糖尿病或高胆固醇。这是自 2014 年以来，第一种被批准用于治疗一般肥胖或超重成人慢性体重管理的药物。该药适用于 BMI 为 27kg/m2 或以上且至少有一种与体重相关疾病的患者，或 BMI 为 30kg/m2 或以上的患者。
司美格鲁肽为肥胖或超重的成年人提供了一种新的治疗方法，与包括减少热量摄入和增加身体活动在内的体重管理计划相结合。
